Full-Time

Clinical Operations Director

Lung Program

4D Molecular Therapeutics

4D Molecular Therapeutics

201-500 employees

Develops gene therapies using AAV vectors

Compensation Overview

$225k - $246k/yr

Remote in USA

Remote

Category
Biology & Biotech (1)
Required Skills
Google Cloud Platform

Get referred to 4D Molecular Therapeutics

Find people who can refer or advise you

Requirements
  • B.S./B.A. in Life Science or related discipline
  • 10+ years of applicable industry experience (Clinical Operations) in drug development
  • 3+ years in a leadership role and with a minimum of 3+ years direct line management experience
  • Relevant experience in clinical trial execution across all phases
  • Proven ability to recruit, retain, organize, and motivate clinical operations personnel
  • Ability to communicate to leadership team on Clinical Operations updates and priorities as well as to advocate for required budget and resources
  • Ability to manage and oversee large scale programs that have corporate-wide impact
  • Ability to develop and manage functional and clinical trial-specific budgets
  • Must be self-motivating; prioritize and manage a large volume of work; show attention to detail
  • Strong interpersonal skills are essential as this individual will partner with various team members and functional groups for clinical trials and business performance
  • Thorough knowledge and understanding of FDA and ICH Guidelines, GCP, medical terminology, and clinical trials
  • Ability to be flexible and adaptable to changing business needs
  • Excellent communication and interpersonal skills
  • Must be able to write clearly and summarize information effectively
  • Must be able to present complex information to various audiences
Responsibilities
  • Develop and execute global clinical operations strategies aligned with corporate objectives, program timelines, budgets, quality standards, and regulatory requirements
  • Provide strategic operational leadership for Phase 1–3 clinical trials, ensuring efficient and compliant study execution across multiple global programs
  • Lead sponsor-side oversight and governance of CROs and critical vendors, including vendor selection, performance management, issue escalation, quality oversight, budget accountability, and operational delivery
  • Proactively identify, assess, and mitigate operational risks impacting timelines, enrollment, quality, budget, or regulatory compliance
  • Drive operational scalability and process optimization while maintaining execution excellence in a lean, fast-paced biotechnology environment
  • Develop and oversee global study timelines, resourcing strategies, and organizational planning across multiple dynamic programs
  • Build, mentor, and lead high-performing Clinical Operations teams, including hiring, talent development, performance management, and organizational growth
  • Partner closely with Therapeutic Area Heads (TAHs), Project Team Leaders (PTLs), Clinical Science, Regulatory Affairs, Biometrics, Quality, and other cross-functional stakeholders to ensure aligned program execution and timely decision-making
  • Serve as Clinical Operations representative and subject matter expert on cross-functional product development teams and governance committees
  • Provide operational leadership and support for clinical trial protocol development, feasibility assessments, country and site strategy, enrollment planning, and study startup activities
  • Lead Clinical Operations contributions to annual budget planning, quarterly forecasting, resource planning, and financial oversight for assigned programs
  • Ensure continuous inspection readiness across clinical programs, including oversight of TMF quality, audit preparedness, CAPA management, and health authority inspection support
  • Partner closely with Quality Assurance to maintain compliance with GCP, FDA, EMA, PMDA, ICH, and other applicable regulatory requirements and quality standards
  • Collaborate with Regulatory Affairs and Clinical Science to support regulatory submissions and ongoing compliance requirements, including ClinicalTrials.gov disclosures and global regulatory obligations
  • Contribute operational expertise to business development and due diligence activities, as applicable
  • Develop and present program updates, operational metrics, key risks, and mitigation strategies to senior leadership and executive management
  • Support development, implementation, and continuous improvement of SOPs, operational processes, and scalable infrastructure to support organizational growth
  • Foster a culture of accountability, collaboration, operational excellence, and clear cross-functional communication
Desired Qualifications
  • Advanced degree in Life Science or related discipline preferred (M.S./M.A., MPH, MHS, MBA)
4D Molecular Therapeutics

4D Molecular Therapeutics

View

4D Molecular Therapeutics develops gene therapies using its Therapeutic Vector Evolution platform to create adeno-associated virus (AAV) delivery vectors that transport therapeutic genes to patients’ cells. This clinical-stage biotech focuses on genetic diseases such as cystic fibrosis, delivering genetic material through engineered AAV vectors in targeted tissues. Its product approach involves R&D and clinical trials to test safety and efficacy, followed by commercialization through direct sales or partnerships with larger pharmaceutical companies. The company differentiates itself with a proprietary vector evolution technology that enables tailored, precise gene delivery and by pursuing funding and collaborations (e.g., with the Cystic Fibrosis Foundation) to advance therapies like 4D-710. The goal is to bring gene therapies to market to treat serious genetic diseases and improve patient outcomes, funded by equity investments, strategic partnerships, and future product sales.

Company Size

201-500

Company Stage

IPO

Headquarters

Emeryville, California

Founded

2013

Get referred to 4D Molecular Therapeutics

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • 4DMT secured $85M upfront plus $50M cost-sharing from Otsuka for 4D-150 in Asia-Pacific, with up to $336M in milestones.
  • 4D-150 showed an 89% reduction in annualized anti-VEGF injection rates in Phase 2 PRISM trial's high-dose group.
  • 4D-710 entered Phase 2 for cystic fibrosis, backed by $32M total funding from the Cystic Fibrosis Foundation and FDA Rare Pediatric Disease designation.

What critics are saying

  • 4FRONT-1 Phase 3 trial of 4D-150 fails to show statistically significant superiority over anti-VEGF bolus injections in wet AMD.
  • 4D-710 Phase 2 trial in cystic fibrosis reveals inadequate CFTR transgene expression or safety issues after aerosol delivery.
  • Otsuka Pharmaceutical revises APAC commercial terms post-approval, reducing 4DMT’s milestone payments by over 30% due to weak uptake.

What makes 4D Molecular Therapeutics unique

  • 4DMT uses proprietary Therapeutic Vector Evolution to create customized AAV vectors like R100 for sustained drug release.
  • 4D-710 is the first genetic medicine achieving CFTR transgene expression in cystic fibrosis lungs via aerosol delivery.
  • 4D-150 provides multi-year sustained anti-VEGF delivery with a single intravitreal injection, reducing treatment burden significantly.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-3%

2 year growth

5%
Stock Titan
Mar 30th, 2026
4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer.

4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer. Filing Impact (Moderate) Filing Sentiment Rhea-AI filing summary. 4D Molecular Therapeutics, Inc. announced a leadership change in its finance function. On March 25, 2026, the Board appointed Kristian Humer as the company's Principal Accounting Officer, effective immediately. He will hold this role in addition to serving as Chief Financial Officer and Principal Financial Officer. Humer succeeds Ashoo Gupta in the Principal Accounting Officer role; Gupta remains Vice President, Finance and Controller. The filing highlights Humer's prior experience as CFO at Foghorn Therapeutics and Viridian Therapeutics and his earlier senior investment banking roles at Citigroup focused on healthcare. 8-K event classification. Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Key figures. Appointment date: March 25, 2026 Age of appointee: 51 years Key terms. Principal Accounting Officer, Principal Financial Officer, Emerging growth company, Item 5.02, +1 more 03/30/2026 - 05:29 PM Faq. What leadership change did 4D Molecular Therapeutics (FDMT) disclose in this 8-K? 4D Molecular Therapeutics disclosed that its Board appointed Kristian Humer as Principal Accounting Officer effective March 25, 2026. He already serves as Chief Financial Officer and Principal Financial Officer, consolidating key finance and accounting responsibilities under a single executive leader. Who is replacing whom as Principal Accounting Officer at 4D Molecular Therapeutics (FDMT)? Kristian Humer is replacing Ashoo Gupta as Principal Accounting Officer at 4D Molecular Therapeutics. Gupta will continue with the company in her existing position as Vice President, Finance and Controller, maintaining continuity in the broader finance organization while shifting the designated accounting officer role. What is Kristian Humer's current role at 4D Molecular Therapeutics (FDMT)? Kristian Humer serves as Chief Financial Officer and Principal Financial Officer and has now been appointed Principal Accounting Officer. This means he oversees the company's overall financial management and is also designated as the primary officer responsible for accounting oversight and related SEC reporting functions. What prior experience does Kristian Humer bring to 4D Molecular Therapeutics (FDMT)? Kristian Humer previously served as Chief Financial Officer at Foghorn Therapeutics and as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics. Before those roles, he spent over a decade at Citigroup Global Markets, most recently as Managing Director in the Healthcare Investment Banking Group. When did the Board of 4D Molecular Therapeutics (FDMT) approve this officer change? The Board of 4D Molecular Therapeutics approved the appointment of Kristian Humer as Principal Accounting Officer on March 25, 2026. The change was effective immediately as of that date, and the company later recorded the event in its current report signed by President and Chief Executive Officer David Kirn. Does Ashoo Gupta remain with 4D Molecular Therapeutics (FDMT) after this change? Yes. Although Ashoo Gupta is no longer designated as Principal Accounting Officer, she continues as Vice President, Finance and Controller. This preserves leadership continuity in the finance team while reassigning the formal Principal Accounting Officer title to Chief Financial Officer and Principal Financial Officer Kristian Humer. Filing exhibits & attachments. 1 document

Calibre One
Jan 13th, 2026
Sam Moskowitz MD appointed as Senior Vice President, Therapeutic Area Head, Lung at 4DMT

Sam Moskowitz MD appointed as Senior Vice President, Therapeutic Area Head, Lung at 4DMT. Congratulations to its client 4D Molecular Therapeutics for appointing Sam Moskowitz MD as Senior Vice President, Therapeutic Area Head, Lung. 4DMT is a leading late-stage biotechnology company developing durable, disease-targeted therapeutics with the potential to transform treatment paradigms and deliver unprecedented patient benefits. Its lead product candidate, 4D-150, is designed as a backbone therapy for blinding retinal vascular diseases, providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) through a single intravitreal injection, significantly reducing the treatment burden of current bolus injections. The lead indication for 4D-150 is wet age-related macular degeneration, now in Phase 3, with diabetic macular edema as a second indication. The Company's second product candidate, 4D-710, is the first known genetic medicine to achieve successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics(TM), 4DMT(TM), Therapeutic Vector Evolution(TM), and the 4DMT logo are trademarks of 4DMT. C1 Team: Christos Richards, Jed Donnelly, Evan Fishel, Leo Cain, & Todd Aghazadeh

Calibre One
Dec 3rd, 2025
Kristian F. Humer appointed as Chief Financial Officer at 4DMT

Kristian F. Humer appointed as Chief Financial Officer at 4DMT. Congratulations to its client 4D Molecular Therapeutics for appointing Kristian F. Humer as Chief Financial Officer. 4DMT is a leading late-stage biotechnology company developing durable, disease-targeted therapeutics with the potential to transform treatment paradigms and deliver unprecedented patient benefits. Its lead product candidate, 4D-150, is designed as a backbone therapy for blinding retinal vascular diseases, providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) through a single intravitreal injection, significantly reducing the treatment burden of current bolus injections. The lead indication for 4D-150 is wet age-related macular degeneration, now in Phase 3, with diabetic macular edema as a second indication. The Company's second product candidate, 4D-710, is the first known genetic medicine to achieve successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics(TM), 4DMT(TM), Therapeutic Vector Evolution(TM), and the 4DMT logo are trademarks of 4DMT. C1 Team: Christos Richards & Leo Cain

Ophthalmology Times
Nov 5th, 2025
4DMT and Otsuka Pharmaceutical partner on 4D-150 in the greater Asia-Pacific region

4DMT and Otsuka Pharmaceutical partner on 4D-150 in the greater Asia-Pacific region. Under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets. 4D Molecular Therapeutics (4DMT) announced a strategic partnership with Otsuka Pharmaceutical to develop and commercialize 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and in the greater Asia-Pacific (APAC) region, including Japan. According to the company, under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets. Additionally, Otsuka will lead all regulatory and commercialization activities in its licensed territories. 4DMT will receive an upfront cash payment of $85 million as well as expected cost sharing of at least $50 million over the next 3 years for global development activities and is eligible for up to $336 million in potential regulatory and commercial milestone payments. 4DMT will retain full development and commercialization rights for 4D-150 outside the APAC region, including the US, Latin America, and Europe. 4D-150 is an investigational agent designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection. It utilizes the company's customized and evolved intravitreal vector, R100. Recently, the company announced positive results from the SPECTRA clinical trial evaluating 4D-150 in patients with DME. The study enrolled 22 patients across 3 dose levels, including the phase 3 dose of 3E10 vg/eye (n=9) and supplemental doses of 1E10 vg/eye (n=12) and 5E9 vg/eye (n=1). It was noted that 2 patients dosed in the 1E10 vg/eye missed over 50% of study visits and were considered not evaluable for injection burden or other efficacy parameters. According to the data, 4D-150 is well-tolerated with no intraocular inflammation at any timepoint over 60 weeks. Additionally, no patients required any modification to the topical corticosteroid regimen. David Kirn, MD, co-founder and CEO of 4DMT, as well as Makoto Inoue, president and representative director of Otsuka Pharmaceutical, commented on the partnership in a press release. "We are thrilled to announce this strategic partnership with Otsuka, a leading global pharmaceutical company with a strong presence in the APAC region, reflecting our shared long-term commitment to improving outcomes for patients with retinal vascular diseases," said Kirn. "This partnership is a key pillar of our global strategy, with 4DMT continuing to lead Phase 3 clinical trial and manufacturing activities globally, in addition to pre-commercial and commercial activities outside the APAC region." "Otsuka has created new value that contributes to the well-being of patients in Japan and around the world through both in-house and collaborative research. By introducing 4D-150 to the markets in Japan and elsewhere in Asia and Oceania, we aim to help prevent vision loss through a single, potentially lifelong administration," added Inoue. * 4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific. Published October 30 2025. Accessed November 3, 2025. * 4DMT announces positive results from SPECTRA trial evaluating 4D-150 in patients with DME. Published August 4, 2025. Accessed November 3, 2025. Don't miss out - get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

The Pharma Letter
Oct 31st, 2025
4DMT secures $85M Otsuka deal

4D Molecular Therapeutics has entered into a deal with Japan's Otsuka Pharmaceutical, granting them exclusive rights to develop and commercialize the gene therapy 4D-150 in Asia-Pacific markets. This agreement secures $85 million upfront to support 4DMT's Phase III program for treating wet age-related macular degeneration and diabetic macular edema.